+43-123-13-985|info@ces.b2sg.org

Arid1a: a fertile target in the parched anticancer drug landscape

By | 2017-05-19T11:28:44+00:00 November 17th, 2016|News|

Recent work from several labs have shown ARID1A, the helicase/ATPase-containing SWI/SNF chromatin-remodeling factor, to be mutated in several cancers, most notably in ovarian cancer (some 50% of ovarian clear-cell carcinoma). Other cancers in which ARID1A was reported to be mutated include Sézary syndrome (a leukemic form of cutaneous T cell lymphoma; ~26%), pancreatic cancer (~25%), breast [...]